glp-1 microdosing Microdosing Ozempic: Benefits, risks and

Administration of exogenous GLP-1 (but not GIP) leads to a significant increase in endogenous insulin secretion

Orandi At 5 years of follow-up, significantly fewer GLP-1 drug users (7.5%) than nonusers (12.2%) experienced death-censored graft loss, for a 49% lower risk for graft loss with GLP-1 drug use when adjusted for insulin use (adjusted subhazard ratio [aSHR] = 0.51

Increases GLP-1 naturally* *Based on preclinical studies Formulated with: Akkermansia muciniphila generates the postbiotics propionate and p9 which induce GLP-1 production

R.ManchandaY.JonesB.PickfordP.InoueA.CarlingD.et al (2021)

doi: 10.1186/s12902-024-01789-w 89 LiuYZhangSChenLHuangXWangMPonikwicka-TyszkoDet al

The clinical trial data provides specific frequency information that helps set realistic expectations